Experimental cancer pill targets Hard-to-Treat gene mutations
Disease control
Terminated
This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated Jun 26, 2026 19:17 UTC